Meihua Medical Completes Over RMB 1 Billion Series B Financing to Build a World-Class Brand in Microbial Diagnostics

VCBeat (WeChat: vcbeat) has learned that Zhuhai Meihua Medical Technology Co., Ltd. (“Meihua Medical”), a leading domestic provider of microbial diagnostic instruments and reagent solutions, recently announced the completion of its Series B financing round, raising over RMB 100 million. The round was co-led by F-Prime Capital and Shanlan Capital, with participation from Zhuhai High-Tech Golden Investment and Qianhe Capital. Zhonghe Capital served as the exclusive financial advisor for this financing round. The proceeds will be primarily allocated to product research and development, while also accelerating the market promotion of its proprietary brands to further expand the company’s market share in the microbial diagnostics industry.

Clinical microbiology testing is regarded by healthcare institutions as the most complex laboratory procedure. It involves processing a wide variety of specimen types, including sputum, urine, feces, blood, and sterile body fluids. The workflow encompasses multiple procedures such as culture and isolation, colony identification, staining and microscopy, species identification, and antimicrobial susceptibility testing, ultimately yielding a report on pathogenic microorganism identification and drug susceptibility.

Rapid clinical microbiological diagnosis is key to improving the success rate of treatment for infected patients, and accelerating the issuance of test reports is an urgent need in clinical microbiological testing. Conventional automated microbiology laboratory testing products are the result of the comprehensive application of mechanical and electronic automation technology, transmission/reflection light (micron-level) identification technology, high-throughput intelligent biochemical microbial culture technology, microbial reproduction metabolite identification technology, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) technology, antibiotic pharmacokinetic decay technology, artificial intelligence and automatic comparison technology, database modeling and library construction technology, and engineering. Microbiology laboratory assembly lines further integrate these testing products by utilizing laboratory automation robots and software system integration to replace manual operations. This enables clinical laboratory personnel to complete microbial specimen testing more efficiently, obtain higher-quality experimental data in the shortest possible time, reduce reliance on specialized manual intervention, and minimize repetitive errors caused by human factors. Consequently, this liberates clinical laboratory personnel from tedious experimental procedures and thoroughly addresses biosafety concerns.

Currently, international brands such as bioMérieux and BD possess core technologies for microbiological testing and capture over 90% of the market share, whereas domestic core technologies in this field remain in their infancy. With China’s growing demand for the precise use of antibiotics, clinical diagnosis and treatment are increasingly reliant on accurate and rapid microbiological diagnostics.

Zhuhai Meihua Medical Technology Co., Ltd., established in 2010, upholds the corporate spirit of “Focusing on Details, Earning Renown Across China,” and specializes in the research, development, and production of comprehensive solutions for clinical microbiology laboratories. The company has consistently adhered to the strategies of “technology substitution” and “import substitution.” In 2017, backed by Series A financing from Beijing Beiken Medical Group and Oriental Fortune Capital, it assembled a team of outstanding scientists from both domestic and international backgrounds. As a result, the company has successfully developed a series of products covering all aspects of microbiology laboratory workflows. These include eight major product lines comprising more than 30 diagnostic instruments and associated reagents: MALDI-TOF mass spectrometry platforms; microbial identification and antimicrobial susceptibility testing analyzers with matching reagents; automated blood culture systems with matching reagents; reproductive tract infection identification and antimicrobial susceptibility testing products; microbiological culture media; pre-analytical specimen processing systems for microbiology; microbiology laboratory management and analysis software; and automated auxiliary equipment for microbiology laboratories. This achievement has laid a solid foundation for the development of fully automated microbiology laboratory assembly lines.

Mr. Wu Yueheng, Founder of Meihua Medical“The data from a study published in The Lancet is worth noting: ‘In 2019, antimicrobial resistance (AMR) infections directly caused 1.27 million deaths and indirectly contributed to 4.95 million deaths worldwide.’ In 2011, the World Health Organization launched the campaign against antimicrobial resistance with the slogan, ‘If we do not act today, there will be no effective medicines tomorrow.’ Leveraging its extensive industry experience, technological innovation capabilities, and international technical background, Zhuhai Meihua Medical Technology Co., Ltd. aims to achieve significant breakthroughs in the field of microbiological testing. We sincerely appreciate the recognition from investors in this funding round and thank our financing partner, Zhonghe Capital.”

Dr. Shi Lei, Partner at STONE Capitalstated: “STO Capital is committed to long-term investments in China’s healthcare ecosystem and has consistently focused on addressing tangible clinical needs. Clinical microbiology diagnostics serve as the gold standard for diagnosing infectious diseases; rapid and accurate diagnosis can effectively facilitate precise clinical treatment, curb microbial resistance, and hold significant importance for both patients and society at large. The team at Zhuhai Meihua Medical Technology Co., Ltd. has been deeply engaged in the field of clinical microbiology testing for many years, continuously expanding its products and business operations, thereby establishing Meihua Medical as a platform enterprise in the clinical microbiology sector. We are delighted to partner with Meihua Medical, supporting its long-term development and working together to build a leading clinical microbiology testing company in China with global ambitions.”

Mr. Duan Yun, Executive Director of Shanlan CapitalHe stated, “Clinical microbiology testing is the gold standard for diagnosing clinical infections and guiding antibiotic therapy. It is also a segment within China’s IVD sector that has developed relatively slowly, with the market long dominated by imported brands. Over many years of accumulation, Zhuhai Meihua Medical Technology Co., Ltd. has established a comprehensive product portfolio in clinical microbiology, spanning culture media reagents, colorimetric/fluorescence-based blood culture detection, antimicrobial susceptibility testing, and mass spectrometry-based pathogen identification, thereby providing relatively complete solutions for clinical microbiology. Shanlan Capital is committed to investing in outstanding medical device and IVD companies that align with China’s healthcare needs. We are optimistic that, under the leadership of Mr. Wu, Zhuhai Meihua Medical will contribute to the development of domestic clinical microbiology, as well as to national efforts to curb antibiotic misuse and control health insurance expenditures.”

Mr. Gou Tongjun, General Manager of Zhuhai High-Tech Gold Investment“It stated: ‘As an outstanding representative of medical device enterprises in the Zhuhai High-Tech Industrial Development Zone, Meihua Medical focuses on the design and R&D of a full range of microbiological testing products, while also providing comprehensive solutions for microbiology laboratories. The team has deep expertise in the field of microbiological testing, with extensive industry experience. Adhering to a strategy of independent R&D and import substitution, it has established a diverse product portfolio encompassing blood culture systems, mass spectrometry, and automated laboratory workflow lines, achieving remarkable results that have drawn significant attention within the industry. We wish Meihua Medical continued growth and development, reaching new heights.’”

Mr. Yan Han, Partner at Qianhe CapitalHe stated, “Globally, microbiological diagnostics account for 20% of the IVD industry share in overseas markets, with its growth rate second only to POCT among various sub-sectors. The clinical demand for microbiological testing is steadily increasing, presenting broad prospects for the development of China’s microbiology and antimicrobial susceptibility testing (AST) diagnostics industry. Qianhe Capital focuses on investing in platform companies that deliver tangible clinical value, possess innovative technologies, and demonstrate strong commercial execution capabilities. We are delighted to become an investor in the company. Under the leadership of its founder, Mr. Wu Yueheng, the Zhuhai Meihua Medical Technology Co., Ltd. team has long been deeply engaged in this field. We hope to serve as a long-term partner throughout the company’s development journey, working together to build it into a leading enterprise in microbiology and AST diagnostics in China.”

Mr. Cao Yue, Chairman of Zhonghe Capital GroupHe stated, “We are delighted to have assisted Zhuhai Meihua Medical Technology Co., Ltd. (Meihua Medical) in completing this round of financing. Zhonghe Capital first met Mr. Wu in 2015, at the early stage of Meihua Medical’s development. Through Mr. Wu’s introduction, we began to closely monitor the growth of China’s microbial diagnostics market. In particular, Meihua Medical entered a phase of rapid expansion in 2020, when its independently developed ‘MALDI-TOF Microbial Mass Spectrometer’ obtained product registration certification. In 2022, Meihua Medical’s project on ‘Research and Development of a Fully Automated Pipeline System for Pathogenic Microorganism Detection’ received support from the National Key R&D Program of the Ministry of Science and Technology of China. This positions Meihua Medical to potentially become the first domestic brand in China to offer an automated microbial diagnostic pipeline system. We believe that in the near future, Meihua Medical will serve as a key driving force for the rapid advancement of China’s domestically produced microbial diagnostics industry.”